These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 32329638)
1. Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis. Geng J; Bao H; Chen Y; Shi L; Geng J; Wang Q; Yu H Expert Rev Anti Infect Ther; 2020 Aug; 18(8):823-834. PubMed ID: 32329638 [TBL] [Abstract][Full Text] [Related]
2. Effect of Telbivudine Versus Other Nucleos(t)ide Analogs on HBeAg Seroconversion and Other Outcomes in Patients with Chronic Hepatitis B: A Network Meta-Analysis. Liang X; Fan R; Sun J; Shaikh J; Taneja A; Gupta S; Hamed K Adv Ther; 2016 Apr; 33(4):519-31. PubMed ID: 26921204 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life. Luo J; Li X; Wu Y; Lin G; Pang Y; Zhang X; Ao Y; Du Z; Zhao Z; Chong Y Int J Med Sci; 2013; 10(4):427-33. PubMed ID: 23471472 [TBL] [Abstract][Full Text] [Related]
4. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Dakin H; Fidler C; Harper C Value Health; 2010 Dec; 13(8):934-45. PubMed ID: 20825624 [TBL] [Abstract][Full Text] [Related]
5. Telbivudine versus entecavir for nucleos(t)ide-naive HBeAg-positive chronic hepatitis B: a meta-analysis. Liu H; Wang X; Wan G; Yang Z; Zeng H Am J Med Sci; 2014 Feb; 347(2):131-8. PubMed ID: 23563307 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B. Ibragimov EK; Abdurakhmanov DT; Rozina TP; Nikulkina EN; Tanaschuk EL; Odintsov AV; Panevkina SV; Moiseev SV Ter Arkh; 2019 Mar; 91(2):40-47. PubMed ID: 31094170 [TBL] [Abstract][Full Text] [Related]
7. HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis. Xing T; Xu H; Cao L; Ye M PLoS One; 2017; 12(1):e0169444. PubMed ID: 28107377 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis. Zhao P; Liu W; Zhao J; Guan Q Virol J; 2011 Feb; 8():75. PubMed ID: 21342505 [TBL] [Abstract][Full Text] [Related]
9. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F; Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133 [TBL] [Abstract][Full Text] [Related]
10. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492 [TBL] [Abstract][Full Text] [Related]
11. Treatment of chronic hepatitis B virus infection - Dutch national guidelines. Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL; Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350 [TBL] [Abstract][Full Text] [Related]
13. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients. Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234 [TBL] [Abstract][Full Text] [Related]
14. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial. Yuen MF; Asselah T; Jacobson IM; Brunetto MR; Janssen HLA; Takehara T; Hou JL; Kakuda TN; Lambrecht T; Beumont M; Kalmeijer R; Guinard-Azadian C; Mayer C; Jezorwski J; Verbinnen T; Lenz O; Shukla U; Biermer M; Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):790-802. PubMed ID: 37442152 [TBL] [Abstract][Full Text] [Related]
16. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Woo G; Tomlinson G; Nishikawa Y; Kowgier M; Sherman M; Wong DK; Pham B; Ungar WJ; Einarson TR; Heathcote EJ; Krahn M Gastroenterology; 2010 Oct; 139(4):1218-29. PubMed ID: 20600036 [TBL] [Abstract][Full Text] [Related]
17. Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials. Wong WWL; Pechivanoglou P; Wong J; Bielecki JM; Haines A; Erman A; Saeed Y; Phoon A; Tadrous M; Younis M; Rayad NZ; Rac V; Janssen HLA; Krahn MD Syst Rev; 2019 Aug; 8(1):207. PubMed ID: 31426837 [TBL] [Abstract][Full Text] [Related]
18. [A retrospective follow-up study of prolonged nucleos(t)ide analogue and interferon combination therapy in HBeAg-positive chronic hepatitis B patients]. Yu SL; Guo CY Zhonghua Gan Zang Bing Za Zhi; 2013 Apr; 21(4):267-70. PubMed ID: 24021787 [TBL] [Abstract][Full Text] [Related]
19. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B. Fan R; Peng J; Xie Q; Tan D; Xu M; Niu J; Wang H; Ren H; Chen X; Wang M; Sheng J; Tang H; Bai X; Wu Y; Zhou B; Sun J; Hou J; J Infect Dis; 2020 Jul; 222(4):611-618. PubMed ID: 32211776 [TBL] [Abstract][Full Text] [Related]
20. Comparison of the forty-eight week efficacy between telbivudine and entecavir in HBeAg-positive Asian patients with chronic hepatitis B: A meta-analysis. Wang N; Hu HD; Sun H; Feng Q; Hu P; Liu Q; Ren H Turk J Gastroenterol; 2013; 24(3):230-40. PubMed ID: 24226716 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]